SCHEMBL1300656

SCHEMBL1300656

COc1nc2c(cc1COc1c(F)cc(F)cc1F)c(=O)c(C(=O)O)cn2[C@H](CO)C(C)C

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ METTL3 Q86U44 1/20 0.45
▸ LMNA P02545 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ ATP6V1B2 P21281 1/20 0.32
▸ TBXA2R P21731 1/20 0.32
▸ EDNRA P25101 1/20 0.32
▸ TARBP2 Q15633 1/20 0.32
▸ RIPK1 Q13546 2/20 0.32
▸ KMT2A Q03164 1/20 0.31
▸ STING1 Q86WV6 1/20 0.31
▸ GSK3B P49841 3/20 0.30
▸ EPHA2 P29317 1/20 0.30
▸ FLT4 P35916 1/20 0.30
▸ RARB P10826 1/20 0.30
▸ TBXAS1 P24557 1/20 0.30
▸ SLC6A3 Q01959 1/20 0.30
▸ CHRM2 P08172 1/20 0.30
▸ DRD1 P21728 1/20 0.30
▸ DPP4 P27487 1/20 0.30
▸ KCNH2 Q12809 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1300658 1.00 METTL3 (0.45) METTL3LMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL12108349 0.90 METTL3 (0.43) METTL3LMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL12110292 0.89 METTL3 (0.47) METTL3LMNAKMT2AGSK3BEPHA2
SCHEMBL12107942 0.88 METTL3 (0.48) METTL3LMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL1300925 0.88 METTL3 (0.35) METTL3RIPK1
SCHEMBL1300683 0.86 METTL3 (0.45) METTL3LMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL1300681 0.86 METTL3 (0.45) METTL3LMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL12108321 0.85 METTL3 (0.44) METTL3LMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL1300517 0.85 METTL3 (0.47) METTL3LMNACYP2C9ATP6V1B2TBXA2R
SCHEMBL12107933 0.85 METTL3 (0.51) METTL3LMNACYP2C9ATP6V1B2TBXA2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE ARDEA BIOSCIENCES, INC. (US) 2011-11-03 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE AARDEA BIOSCIENCES, INC. (US) 2011-07-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166123-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885LMNA 1312/4885CYP2C9 2322/4885
US-20110269741-A1 NOVEL COMPOSITIONS AND METHODS OF USE TYMP, SAMHD1, PNP METTL3 2709/4885LMNA 1312/4885CYP2C9 2322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback